As of 19 Nov 2026, ArkeaBio has raised $15M across 1 verified round on record; latest: $15 million Series A extension led by AgriZeroNZ, announced 29 Sep 2026.
A company developing a vaccine intended to reduce methane produced by cattle and other ruminants.
arkeabio.comLinkedInBoston, Massachusetts, United StatesClimateFounded 2021
8 sources · checked 25 times, last 26d ago
Source 2 calls the participant “Breakthrough Energy Ventures,” while the more specific source calls it “Breakthrough Energy”; the latter is used.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A ext. Series A extension round | $15M | 2026-09-29 | AgriZeroNZ | No recent discussion |
8 sources · checked 25 times, last 26d ago [ VERIFIED · CORRECTED ] read against 4 of 8 sources
Source 2 calls the participant “Breakthrough Energy Ventures,” while the more specific source calls it “Breakthrough Energy”; the latter is used. | ||||
ArkeaBio develops a safe, cost-effective vaccine to reduce methane emissions from cattle for farmers and producers worldwide.
ArkeaBio is targeting enteric methane from cattle and other ruminants, a major agricultural climate problem, with a vaccine the company says could reach pasture-based animals that daily feed additives cannot. Its disclosed financing is funding research, farmer pilots and field trials aimed at turning proof of concept into a scalable product, with first revenue reported as a possibility around 2028.
Checked against 10 sources on Sep 30
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Series A1 | $7 million | 2025-09-23 | Breakthrough Energy Ventures, AgriZeroNZ | |
Also named as backers in company research: The Grantham Foundation for the Protection of the Environment, Rabo Ventures, Overview Capital, The51 Food & AgTech Fund